📰 Seth Lederman News
Seth Lederman News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Seth Lederman. Real-time updates on events, politics, business and more.
March 11, 2024
11.03.2024 - Phase 3 RESILIENT study of Tonmya met its primary endpoint of daily pain reduction (p=0.00005) and achieved statistically significant improvement on all six key pre-specified secondary endpoints with effect sizes on sleep, fatigue, FIQ-R symptoms ... Seite 1
February 29, 2024
CHATHAM, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical ...
February 29, 2024
Additional data from recently reported positive Phase 3 RESILIENT trial will be presentedCHATHAM, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer, will present at The 6th International Congress on Controversies in Fibromyalgia in Brussels, Belgium on March 7, 2024. The pres
February 28, 2024
Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to share significant news regarding the companys latest development: the clearance of the Investigational New Drug...
February 27, 2024
People with fibromyalgia pain are closer to a new option for treatment that targets their characteristically poor sleep quality.
February 27, 2024
Tonix Pharmaceuticals Holding Corp. (TNXP), Tuesday announced that it is planning for regulatory filings in Japan, China and the U.S., following the positive results from its clinical pharmacokinetic bridging study of Tonmya.
February 27, 2024
27.02.2024 - Tonix plans to File a Clinical Trial Notification (CTN) in Japan and Investigational New Drug (IND) application in China to support a registration-enabling Asian Phase 3 study without dosage adjustment based on U.S. registrational Phase 3 data ... Seite 1
February 27, 2024
Tonix Pharmaceuticals Holding Corp. (TNXP), Tuesday announced that it is planning for regulatory filings in Japan, China and the U.S., following the positive results from its clinical pharmacokinetic bridging study of Tonmya.
February 23, 2024
New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series...
February 16, 2024
New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT...